146 related articles for article (PubMed ID: 7384094)
41. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
[TBL] [Abstract][Full Text] [Related]
42. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
43. Improved metastatic animal model of human prostate carcinoma using surgical orthotopic implantation (SOI).
Chang XH; Fu YW; Na WL; Wang J; Sun H; Cai L
Anticancer Res; 1999; 19(5B):4199-202. PubMed ID: 10628375
[TBL] [Abstract][Full Text] [Related]
44. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
[TBL] [Abstract][Full Text] [Related]
45. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
46. Bloodborne biomolecular markers in prostate cancer development and progression.
Bok RA; Small EJ
Nat Rev Cancer; 2002 Dec; 2(12):918-26. PubMed ID: 12459730
[TBL] [Abstract][Full Text] [Related]
47. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.
Pinthus JH; Waks T; Schindler DG; Harmelin A; Said JW; Belldegrun A; Ramon J; Eshhar Z
Cancer Res; 2000 Dec; 60(23):6563-7. PubMed ID: 11118033
[TBL] [Abstract][Full Text] [Related]
48. Models for prostate cancer.
Prog Clin Biol Res; 1980; 37():1-397. PubMed ID: 7384080
[No Abstract] [Full Text] [Related]
49. Molecular markers and determinants of prostate cancer metastasis.
Gopalkrishnan RV; Kang DC; Fisher PB
J Cell Physiol; 2001 Dec; 189(3):245-56. PubMed ID: 11748582
[TBL] [Abstract][Full Text] [Related]
50. Autochthonous mouse models for prostate cancer: past, present and future.
Huss WJ; Maddison LA; Greenberg NM
Semin Cancer Biol; 2001 Jun; 11(3):245-60. PubMed ID: 11407949
[TBL] [Abstract][Full Text] [Related]
51. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
52. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
[TBL] [Abstract][Full Text] [Related]
53. In vivo models of human prostate cancer bone metastasis.
Brown JM
Methods Mol Med; 2003; 81():149-62. PubMed ID: 12725119
[No Abstract] [Full Text] [Related]
54. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
55. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
56. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
57. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
58. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
59. Genetic deficiency in Pparg does not alter development of experimental prostate cancer.
Saez E; Olson P; Evans RM
Nat Med; 2003 Oct; 9(10):1265-6. PubMed ID: 12960963
[TBL] [Abstract][Full Text] [Related]
60. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
